Treat To Target In Gout Can Reduce The Risk Of Flares By More Than 70 Having low levels of uric acid, a metabolism byproduct, can reduce your risk of having gout flares. following a treat to target approach in gout means picking a goal uric acid level and adjusting medication doses until you reach it. Medication adherence in gout is low, and discontinuation of urate lowering therapy puts patients at risk of flares and cardiovascular events.
Gout Flares Treatment Ilaris Canakinumab Those receiving guideline concurrent treat to target care were more than three times as likely to achieve serum urate (su) goals of <360 umol l (<6.0 mg dl) and importantly were 67% less likely to experience two or more gout flares during the second year of follow up. In a few long term studies (over 12 months), treat to target interventions have been shown to help reduce tophi, decrease gout flare frequency, and improve mri detected synovitis. After optimizing hospital gout care, more than 90% of patients were initiated on urate lowering therapy. significant relative improvements in urate target attainment were seen following a single, nurse led, post discharge appointment. In a nurse led treat to target trial, nearly all patients in the nurse led therapy group achieved the serum urate target of 360 μmol l (95%), resulting in a 67% lower risk of flares compared with the standard care group (where only 30% hit the target).
Gout Flares During The Initiation And Escalation Of Treat To Target After optimizing hospital gout care, more than 90% of patients were initiated on urate lowering therapy. significant relative improvements in urate target attainment were seen following a single, nurse led, post discharge appointment. In a nurse led treat to target trial, nearly all patients in the nurse led therapy group achieved the serum urate target of 360 μmol l (95%), resulting in a 67% lower risk of flares compared with the standard care group (where only 30% hit the target). To improve the management of gout in clinical practice, a core group was convened to discuss and develop consensus recommendations aimed at defining a treatment target and initiate a t2t programme for gout. In this review we consider the rationale for the treat to target urate strategy when using urate lowering therapy, potential definitions of a “treat to avoid symptoms” strategy, or perhaps what is not “treat to avoid symptoms”, and approaches that might address this uncertainty. Conclusion: in this post hoc analysis from a large, randomized double blind, non inferiority trial, we found that su achievement following a t2t strategy was associated with a 60% greater odds of remaining flare free between 49 and 72 weeks of follow up. Well designed, prospective trials have demonstrated that a treat to target strategy, compared to usual care, resulted in better patient compliance, reduced gout flares, less tophi, and improved quality of life.
Gout Flares During The Initiation And Escalation Of Treat To Target To improve the management of gout in clinical practice, a core group was convened to discuss and develop consensus recommendations aimed at defining a treatment target and initiate a t2t programme for gout. In this review we consider the rationale for the treat to target urate strategy when using urate lowering therapy, potential definitions of a “treat to avoid symptoms” strategy, or perhaps what is not “treat to avoid symptoms”, and approaches that might address this uncertainty. Conclusion: in this post hoc analysis from a large, randomized double blind, non inferiority trial, we found that su achievement following a t2t strategy was associated with a 60% greater odds of remaining flare free between 49 and 72 weeks of follow up. Well designed, prospective trials have demonstrated that a treat to target strategy, compared to usual care, resulted in better patient compliance, reduced gout flares, less tophi, and improved quality of life.
Comments are closed.